INSMED Inc
INSMdata completeness 100%17 fiscal years on fileINSMED Inc earns about -39% on invested capital, but has diluted owners by 78% over 5 years — worth asking whether the growth reaches owners. The cash-flow models don't apply cleanly here — the ledger says why below.Whether it’s worth owning at today’s price is the last question — and yours to answer, below.
| Figure | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|
| Revenue | $188.5M1 | $245.4M2 | $305.2M3 | $363.7M3 | $606.4M3 |
| Net income | −$434.7M4 | −$481.5M5 | −$749.6M6 | −$913.8M6 | −$1.28B6 |
| Operating cash flow | −$363.3M7 | −$400.4M8 | −$536.2M9 | −$683.9M9 | −$935M9 |
| Capital expenditure | $7.29M10 | $9.88M11 | $13.3M12 | $21.9M12 | $32.6M12 |
| Free cash flow (derived) | −$370.6M7 | −$410.3M8 | −$549.5M9 | −$705.8M9 | −$967.6M9 |
| Total debt | $1.37B13 | $2.28B14 | $2.33B15 | $2.23B16 | $1.09B16 |
| Cash & equivalents | $716.8M17 | $1.07B18 | $482.4M19 | $555M20 | $510.4M20 |
| Diluted shares | 112.1M | 123.0M | 140.4M | 164.0M | 199.0M |
Superscripts are receipts. Each links to the SEC filing the number came from (full list at the bottom).
10 shares is a claim on $37.13 of net worth that earned you −$64.16 and generated −$48.62 of cash last year, against $54.66 of debt.
It earned an average -39% on invested capital over 5 years. Compare that to what it costs to fund the business.
seeing a moat in the numbers →Share count is up 78% over 5 years — owners have been diluted. Worth asking what they got for it. Total debt has fallen 20% — deleveraging.
reading capital allocation →Signals, not verdicts — read from the filings above. Numbers don’t prove a moat; they show its footprint. You decide.
Different models answer different questions — which to trust when →
- 10-K · period ending 2021-12-31 · accession 0001104506-24-000008 (RevenueFromContractWithCustomerExcludingAssessedTax)
- 10-K · period ending 2022-12-31 · accession 0001104506-25-000009 (RevenueFromContractWithCustomerExcludingAssessedTax)
- 10-K · period ending 2023-12-31 · accession 0001104506-26-000009 (RevenueFromContractWithCustomerExcludingAssessedTax)
- 10-K · period ending 2021-12-31 · accession 0001104506-24-000008 (NetIncomeLoss)
- 10-K · period ending 2022-12-31 · accession 0001104506-25-000009 (NetIncomeLoss)
- 10-K · period ending 2023-12-31 · accession 0001104506-26-000009 (NetIncomeLoss)
- 10-K · period ending 2021-12-31 · accession 0001104506-24-000008 (NetCashProvidedByUsedInOperatingActivities)
- 10-K · period ending 2022-12-31 · accession 0001104506-25-000009 (NetCashProvidedByUsedInOperatingActivities)
- 10-K · period ending 2023-12-31 · accession 0001104506-26-000009 (NetCashProvidedByUsedInOperatingActivities)
- 10-K · period ending 2021-12-31 · accession 0001104506-24-000008 (PaymentsToAcquirePropertyPlantAndEquipment)
- 10-K · period ending 2022-12-31 · accession 0001104506-25-000009 (PaymentsToAcquirePropertyPlantAndEquipment)
- 10-K · period ending 2023-12-31 · accession 0001104506-26-000009 (PaymentsToAcquirePropertyPlantAndEquipment)
- 10-K · period ending 2021-12-31 · accession 0001104506-23-000009 (LongTermDebtNoncurrent)
- 10-K · period ending 2022-12-31 · accession 0001104506-24-000008 (LongTermDebtNoncurrent)
- 10-K · period ending 2023-12-31 · accession 0001104506-25-000009 (LongTermDebtNoncurrent)
- 10-K · period ending 2024-12-31 · accession 0001104506-26-000009 (LongTermDebtNoncurrent)
- 10-K · period ending 2021-12-31 · accession 0001104506-23-000009 (CashAndCashEquivalentsAtCarryingValue)
- 10-K · period ending 2022-12-31 · accession 0001104506-24-000008 (CashAndCashEquivalentsAtCarryingValue)
- 10-K · period ending 2023-12-31 · accession 0001104506-25-000009 (CashAndCashEquivalentsAtCarryingValue)
- 10-K · period ending 2024-12-31 · accession 0001104506-26-000009 (CashAndCashEquivalentsAtCarryingValue)